C1orf162: A Potential Drug Target Or Biomarker (G128346)

Target Name: C1orf162

NCBI ID: G128346

C1orf162

C1orf162: A Potential Drug Target Or Biomarker

C1orf162, also known as Chromosome 1 open reading frame 162, and its transcript variant 1, is a gene that has been identified as a potential drug target or biomarker for various diseases. The gene is located on Chromosome 1 and encodes a protein known as CRLF1 (C-terminal region-containing gene 1).

The C1orf162 gene has been associated with a number of cellular processes, including cell adhesion, migration, and the regulation of ion channels. It is also involved in the development and maintenance of the blood-brain barrier, which is a critical barrier that separates the brain from the surrounding bloodstream.

In addition to its role in cellular processes, C1orf162 has also been shown to play a role in several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

One of the most promising aspects of C1orf162 as a drug target is its potential to treat a wide range of diseases, including neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and can have a significant impact on an individual's quality of life.

C1orf162 has also been shown to be involved in the development and progression of cancer, including brain tumors. By targeting the C1orf162 gene, researchers may be able to develop new treatments for a variety of cancer types.

In addition to its potential as a drug target, C1orf162 has also been identified as a potential biomarker for several diseases. For example, C1orf162 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and may be a useful diagnostic marker for this disorder.

Another potential application of C1orf162 as a biomarker is its involvement in the development of neurodegenerative disorders. By studying the expression of C1orf162 in the brains of individuals with neurodegenerative disorders, researchers may be able to identify new biomarkers for these disorders and develop new treatments.

Overall, C1orf162 is a gene that has significant potential as a drug target or biomarker for a wide range of diseases. Further research is needed to fully understand its role in these processes and to develop new treatments based on this gene.

Protein Name: Chromosome 1 Open Reading Frame 162

The "C1orf162 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1orf162 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets